BioAge expands BGE-102 into eye disease with a planned Phase 1b/2a trial in diabetic macular edema

BioAge Labs/BGE-102 (NLRP3)

BioAge announced a Phase 1b/2a proof-of-concept trial of oral BGE-102 in diabetic macular edema planned for mid-2026, aiming to provide an oral alternative to eye injections.

• Phase 1b/2a randomized trial tests BGE-102 as monotherapy and with VEGF inhibitor therapy; primary endpoint is intraocular IL-6 change.
• Preclinical data showed BGE-102 provided near-complete protection from vascular leakage and 90% preservation of microvascular integrity.
• Results expected mid-2027; expansion into other inflammation-driven retinal diseases planned if successful.